ABBVIE
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea
- Conditions
- Psoriasis
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2
- Registration Number
- NCT03925441
- Locations
- π°π·
Ajou University Hospital /ID# 207843, Suwon-si, Gyeonggido, Korea, Republic of
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 243
- Registration Number
- NCT03926169
- Locations
- π«π·
HCL - Hopital Edouard Herriot /ID# 218408, Lyon, France
πΊπΈMinnesota Clinical Study Center /ID# 211979, New Brighton, Minnesota, United States
πΊπΈBurke Pharmaceutical Research /ID# 211671, Hot Springs, Arkansas, United States
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders,Generalized Anxiety Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 273
- Registration Number
- NCT03924323
- Locations
- πΊπΈ
UH Cleveland Medical Center /ID# 233373, Cleveland, Ohio, United States
πΊπΈCenter for Psychiatry and Behavioral Medicine Inc /ID# 233355, Las Vegas, Nevada, United States
πΊπΈATP Clinical Research, Inc /ID# 233362, Costa Mesa, California, United States
A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT03924947
- Locations
- πΊπΈ
Virginia Commonwealth University Medical Center Main Hospital /ID# 164574, Richmond, Virginia, United States
πΊπΈNationwide Children's Hospital /ID# 225628, Columbus, Ohio, United States
πΊπΈUniversity of Iowa Hospitals and Clinics /ID# 164551, Iowa City, Iowa, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 65
- Registration Number
- NCT03922607
- Locations
- πΊπΈ
Total Skin and Beauty Derm Ctr /ID# 222593, Birmingham, Alabama, United States
πΊπΈAnaheim Clinical Trials LLC /ID# 213645, Anaheim, California, United States
πΊπΈDermatology Res. Assoc., CA /ID# 224980, Los Angeles, California, United States
Expanded Access to Risankizumab
- Conditions
- Crohn's DiseaseUlcerative Colitis (UC)
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03914261
Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa (HS)
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 46
- Registration Number
- NCT03894956
- Locations
- π―π΅
Anjou Kousei Hospital /ID# 216741, Anjo-shi, Aichi, Japan
π―π΅Kimitsu Chuo Hospital /ID# 214733, Kisarazu-shi, Chiba, Japan
π―π΅NHO Nagoya Medical Center /ID# 214406, Nagoya-shi, Aichi, Japan
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorsCancerTriple-Negative Breast Cancer (TNBC)Non-small-cell-lung-cancer (NSCLC)Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT03893955
- Locations
- πͺπΈ
Hospital Universitario Fundacion Jimenez Diaz /ID# 212806, Madrid, Spain
π¦πΊIcon Cancer Centre /ID# 224084, South Brisbane, Queensland, Australia
πΊπΈFort Wayne Medical Oncology and Hematology, Inc /ID# 226072, Fort Wayne, Indiana, United States
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- Interventions
- Other: Standard of Care
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 600
- Registration Number
- NCT03891446
- Locations
- πΊπΈ
Lakeside Vision Center /ID# 240204, Irvine, California, United States
πΊπΈThe Eye Research Foundation /ID# 240186, Newport Beach, California, United States
πΊπΈWolstan & Goldberg Eye Associates /ID# 240221, Torrance, California, United States
A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 82
- Registration Number
- NCT03886220
- Locations
- πΊπΈ
Johns Hopkins University /ID# 211135, Baltimore, Maryland, United States
πΊπΈCaceres Specialized Gynecology /ID# 214956, Kissimmee, Florida, United States
πΊπΈGeorgia Research for Women /ID# 211321, Atlanta, Georgia, United States